RALGAPB

Across TCGA pan-cancer cohorts, RALGAPB mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of RALGAPB’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where RALGAPB mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types RALGAPB is over-expressed in tumor, although a few such as CCRCC and LSCC show the opposite, repressed pattern.

CCRCC, LSCC, and HNSC are the cancer types where RALGAPB tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RALGAPB mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	IV	−0.401	<.001	12	view →
LSCC	Female	All	−0.337	<.001	8	view →
HNSC	Male	All	−0.097	.006	5	view →
COAD	Female	III,IV	+0.129	.004	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

RALGAPB–CCRCC

Open the CCRCC breakdown →